Optimizing capping efficiency and poly(A) tail length for high translation
Reducing innate immune recognition of the RNA
Scaling production for clinical and commercial needs
Uncontrollable Self-Amplification of saRNA
Fluctuating Translation Efficiency of mRNA
Large self-amplifying RNA constructs for prolonged antigen expression.
Incorporation of modified nucleotides (e.g., N1-Methylpseudouridine) to enhance stability and reduce immunogenicity.
Partnership options for lipid nanoparticle encapsulation.
Proprietary enzymes and processes ensure high yields of full-length RNA.
Rigorous testing for identity, purity, integrity, and functionality (e.g., capping efficiency).
Manufacturing processes scalable to clinical and commercial grades.
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
